Close X
Thursday, November 28, 2024
ADVT 
National

First trials of Ebola vaccines suggest they are safe; next phase next month: WHO

Darpan News Desk The Canadian Press, 09 Jan, 2015 10:24 AM

    The first clinical trial designed to see if two experimental Ebola vaccines actually work may begin in late January and two others are slated to start in February in West Africa, the World Health Organization said Friday.

    Manufacturers of the two most advanced experimental vaccines need more time to determine how much vaccine each person might need for the product to work, said Dr. Marie-Paule Kieny, the WHO's point person for efforts to develop and deploy Ebola vaccines and drugs.

    Kieny revealed the news at a press conference in Geneva called to report on a special vaccine summit with manufacturers and researchers that the WHO hosted on Thursday.

    Kieny said the two leading manufacturers — GSK and a partnership between NewLink Genetics and Merck — are still analyzing data from small Phase 1 trials of the vaccines that are taking place in a number of sites in the United States, Canada, Europe and several African countries not currently fighting Ebola.

    Phase 1 trials are designed to see if a product is safe to use and to determine what the dose for a drug or vaccine should be. They are followed by larger Phase 2 and 3 trials that are designed to show if an experimental product actually works.

    It will take the manufacturers another two to four weeks to be able to determine an appropriate dose, Kieny said.

    That is a delay on previous plans. It had been hoped the first and the largest of the trials would start in Liberia by mid-January.

    The delays in getting the next stage of clinical trials off the ground is raising concerns that the trials may not come up with definitive answers about whether the vaccines work.

    In order to show that a vaccine is efficacious, clinical trials vaccinate some people and leave others unprotected. If more cases are seen among those who didn't get the vaccine, it is signal that the serum is offering protection.

    But with the rate of growth of new cases actually falling in many parts of the Ebola outbreak zone, there may not be enough transmission of the virus to be able to show that a vaccine works, some observers fear.

    Kieny said the organizers of the Liberian trial are prepared to expand the number of people to be included in the trial if needed. Their statistical analysis suggests they should still be able to reach an answer, she said.

    She noted, though, that at this point it seems most likely that a trial planned for Guinea might be the one that will give the earliest clue as to whether the vaccines work.

    Two trials are planned for Guinea. One is an observational study, in which health-care workers will be vaccinated. They will be watched to see if new infections among health-care workers drop off after the vaccination.

    Another — the one Kieny suggested might show signs of efficacy — involves a design called ring vaccination, in which people who are contacts of known cases will be vaccinated to try to prevent onward transmission.

    People in some rings will be vaccinated immediately after a case is identified and others will be vaccinated after a delay. If there are fewer new cases among the contacts who were vaccinated quickly, it would suggest the vaccines are protective.

    Kieny said organizers of that trial plan to vaccinate 4,500 contacts quickly and another 4,500 after a delay.

    The NewLink-Merck vaccine was designed by scientists at Canada's National Microbiology Laboratory in Winnipeg, while the GSK product was designed by researchers at the U.S. National Institutes of Health.

    Kieny said a third manufacturer, Johnson & Johnson, indicated it is devising plans to do an efficacy trial of another Ebola vaccine later in the year. The company's vaccine started Phase 1 testing this week in Britain.

    Their vaccine requires two doses, a priming dose followed by a booster some weeks later. That is not an optimal strategy in an outbreak, because of the amount of time it would take to protect people.

    But Kieny said there was discussion at the meeting about potentially developing two types of Ebola vaccines, one which could be used to develop immunity quickly in an outbreak setting and another that could be given in advance of exposure to people like health-care workers who might at some point encounter Ebola.

    MORE National ARTICLES

    Court upholds pardon revocation for alleged Via Rail terror plotter

    Court upholds pardon revocation for alleged Via Rail terror plotter
    TORONTO — There is no evidence of any political interference in a decision to revoke the criminal pardon of a man accused of plotting to attack a passenger train, a Federal Court judge has ruled.

    Court upholds pardon revocation for alleged Via Rail terror plotter

    Hearing Delayed For Prohibited Driver Who Killed B.C. Woman At Crosswalk

    Hearing Delayed For Prohibited Driver Who Killed B.C. Woman At Crosswalk
    KAMLOOPS, B.C. — A chronic prohibited driver who struck and killed a woman at a crosswalk in Kamloops, B.C., has had his appeal hearing delayed for nearly a month.

    Hearing Delayed For Prohibited Driver Who Killed B.C. Woman At Crosswalk

    Annapolis Warship To Be Sunk As Largest Artificial Reef In Vancouver Area

    Annapolis Warship To Be Sunk As Largest Artificial Reef In Vancouver Area
    The Artificial Reef Society of B.C. says the former HMCS Annapolis will be towed from Long Bay to nearby Halkett Bay on Jan. 13 before being sunk four days later.

    Annapolis Warship To Be Sunk As Largest Artificial Reef In Vancouver Area

    Crude-by-rail volumes expected to grow in 2015 despite price volatility

    Crude-by-rail volumes expected to grow in 2015 despite price volatility
    MONTREAL — Volatility in energy prices is expected to be a "wild card" for Canadian railways in the long term, but crude-by-rail volumes should continue to grow, albeit more slowly, in 2015, an industry analyst said Tuesday.

    Crude-by-rail volumes expected to grow in 2015 despite price volatility

    B.C. Students' Space Project Delayed By Oct. Rocket Crash Delayed Again

    B.C. Students' Space Project Delayed By Oct. Rocket Crash Delayed Again
    KAMLOOPS, B.C. — A science project dreamed up by a group of students in central British Columbia that exploded on a rocket launching pad almost two months ago is on hold again.

    B.C. Students' Space Project Delayed By Oct. Rocket Crash Delayed Again

    Deportation of imprisoned Canadian-Egyptian journalist in 'final stages': family

    Deportation of imprisoned Canadian-Egyptian journalist in 'final stages': family
    CAIRO — The family of a Canadian-Egyptian journalist imprisoned in Cairo says they have requested his deportation and were told by a senior official the process is in its "final stages."

    Deportation of imprisoned Canadian-Egyptian journalist in 'final stages': family